Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $305M Series F for AI peptides targeting undruggable cancer proteins (Jan 2026).
Parabilis Medicines is a clinical-stage biotechnology company applying AI to the design of peptide-based therapeutics targeting proteins previously considered undruggable, with a primary focus on oncology. The company was founded on the insight that AI-optimized peptides — short chains of amino acids — can be engineered to reach and modulate intracellular protein targets that small molecules and biologics cannot access. Parabilis uses proprietary computational platforms to design, screen, and optimize peptide candidates with improved cell permeability, stability, and target selectivity.\n\nThe company's pipeline is centered on cancer proteins that drive tumor growth but lack conventional binding pockets for small molecule inhibition. Parabilis's AI-designed peptides are engineered to penetrate cancer cells and disrupt these oncogenic interactions, potentially unlocking entirely new therapeutic options for patients with tumors driven by these targets. The approach also has potential applications in other diseases where intracellular protein-protein interactions are central to pathology.\n\nParabilis raised $305M in a Series F round in January 2026, one of the largest biotech fundraises of that period. The financing was designed to advance its lead programs through clinical development and expand its pipeline of AI-designed peptide candidates. With over $300M in fresh capital, Parabilis is one of the most heavily funded companies in the emerging AI peptide therapeutics space, positioning it to compete with both traditional peptide drug developers and newer AI-native biotech platforms.
FY2025 (ended Mar 31, 2025): JPY 21.6887T (+6.2%) | Operating Profit: JPY 1.2134T (-12.2%) | FY2024: JPY 20.4286T (+20.8%) | Q3 FY2024 (9 months): Op Profit JPY 1.1399T, margin 7.0% | Auto sales down 297k (Asia impact) | FY2026 guidance: Net profit JPY 250B (-70.1%), Revenue JPY 20.3T (-6.4%)
Honda Motor Co., Ltd. is a Japanese multinational mobility conglomerate founded in 1948 by Soichiro Honda and Takeo Fujisawa in Hamamatsu, Japan. Starting as a motorcycle manufacturer, Honda expanded into automobiles, power equipment, marine engines, and aerospace, becoming one of the largest and most diversified mobility companies in the world. With over 90 million vehicles sold globally and a reputation built on engineering reliability, fuel efficiency, and innovation, Honda operates manufacturing facilities across more than 30 countries on six continents.\n\nHonda's automotive lineup ranges from mass-market sedans and SUVs — including the best-selling Civic and CR-V — to trucks, minivans, and the premium Acura brand. The company is executing a major pivot to electrification through the Honda 0 Series, a new EV architecture designed from the ground up for battery-electric vehicles launching in 2026. Honda's partnership with General Motors on battery technology, combined with its investment in solid-state battery development, reflects a multi-path electrification strategy designed to hedge technology risk while building scale.\n\nHonda reported FY2025 revenue of JPY 21.7 trillion, a 6.2% year-over-year increase, driven by strong North American demand and favorable currency tailwinds. The company faces intensifying competition from Chinese EV manufacturers in Asia and is exploring a potential merger with Nissan as part of broader Japanese automotive consolidation. Honda's engineering culture, global manufacturing scale, and brand credibility in reliability position it as a resilient and well-capitalized incumbent navigating the EV transition.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.